form 4 Form 4 — FPN General Partner LLC 2026-03-02 View Filing form 4 Form 4 — Flagship Pioneering Fund VI General Partner LLC 2026-03-02 View Filing form 4 Form 4 — Flagship VentureLabs VI Manager ...

Agoyu integrated its AI moving quote tool into select Realtor.com rental and for-sale listings. Users record a short video of belongings, and the AI estimates weight and volume to deliver real time ...

Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using artificial intelligence and machine learning to create protein-based medicines. The company operates in the ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

If vanilla AI image generators leave you feeling underwhelmed, it's time to play with the spicy stuff. I put the most popular NSFW options to the test so you can find the one that really hits the mark ...

Driving an RV lets you bring the comforts of home along on your road trip, but having a portable generator is essential. It powers your electric appliances and charges electronics, like your phone and ...

I'm an independent creator passionate about building useful tools, simulations, and theories that make complex ideas more accessible. I explore the intersection of technology, education, and human ...

Rebar, a startup building an AI operating system for commercial HVAC suppliers, has raised $14 million in a Series A funding round, it tells Crunchbase News exclusively. Founded in October 2024, Rebar ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...